1UB Stock Overview
Operates as a technology company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Cognetivity Neurosciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.11 |
| 52 Week Low | CA$0.0005 |
| Beta | -0.35 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.51% |
| 33 Year Change | -99.90% |
| 5 Year Change | -99.49% |
| Change since IPO | -99.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1UB | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.9% | 0.8% |
| 1Y | -99.5% | -4.7% | 8.6% |
Return vs Industry: 1UB underperformed the German Medical Equipment industry which returned 8.7% over the past year.
Return vs Market: 1UB underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| 1UB volatility | |
|---|---|
| 1UB Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1UB's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 1UB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Sina Habibi | cognetivity.com |
Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia; and OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd.
Cognetivity Neurosciences Ltd. Fundamentals Summary
| 1UB fundamental statistics | |
|---|---|
| Market cap | €625.21k |
| Earnings (TTM) | -€5.78m |
| Revenue (TTM) | €66.14k |
9.5x
P/S Ratio-0.1x
P/E RatioIs 1UB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1UB income statement (TTM) | |
|---|---|
| Revenue | CA$98.97k |
| Cost of Revenue | CA$1.36m |
| Gross Profit | -CA$1.27m |
| Other Expenses | CA$7.38m |
| Earnings | -CA$8.64m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.092 |
| Gross Margin | -1,278.71% |
| Net Profit Margin | -8,732.77% |
| Debt/Equity Ratio | -19.9% |
How did 1UB perform over the long term?
See historical performance and comparison